Literature DB >> 31383483

Widefield OCT-Angiography and Fluorescein Angiography Assessments of Nonperfusion in Diabetic Retinopathy and Edema Treated with Anti-Vascular Endothelial Growth Factor.

Aude Couturier1, Pierre-Antoine Rey2, Ali Erginay2, Carlo Lavia2, Sophie Bonnin2, Bénédicte Dupas2, Alain Gaudric2, Ramin Tadayoni2.   

Abstract

PURPOSE: To assess change in retinal nonperfusion (NP) after anti-vascular endothelial growth factor (VEGF) therapy for diabetic macular edema (DME) using 2 different imaging modalities: swept-source widefield (SS-WF) OCT angiography (OCTA) and ultra-widefield (UWF) fluorescein angiography (FA).
DESIGN: Observational case series. PARTICIPANTS: Ten eyes of 9 patients with severe nonproliferative diabetic retinopathy (NPDR) or proliferative DR (PDR) initiating 3 monthly anti-VEGF intravitreal injections for DME.
METHODS: All eyes were imaged with UWF color fundus photographs (CFPs), UWF FA, and SS-WF OCTA at baseline (M0) and 1 month after the third anti-VEGF injection (M3). All images were aligned and divided into 16 boxes for analysis of NP areas by 2 blinded retina specialists. MAIN OUTCOME MEASURES: The number of discrepancies between SS-WF OCTA and UWF FA regarding the detection of NP areas and small vessels passing through NP areas; assessment of DR severity on UWF CFP; and change in each NP area between M0 and M3: number of boxes/eye with presence of at least 1 NP area, number of arterioles or venules that disappeared or reappeared, and number of NP areas in which capillaries disappeared or reappeared.
RESULTS: The diabetic retinopathy (DR) severity score improved by at least 1 stage in 8 of 10 eyes, with a significant decrease in the mean number of microaneurysms and retinal hemorrhages on UWF CFP at M3 versus M0 (n = 40±28 vs. 121±57; P = 0.0020) and regression of fundus neovascularization when present. All NP areas detected on FA were seen on SS-WF OCTA, but additional NP areas were detected on SS-WF OCTA at M0 in 29% (46/160) of boxes. No reperfusion of arterioles or venules was observed at M3 on FA or SS-WF OCTA. Retinal capillaries were only visible on OCTA, and no reperfusion in NP areas was observed even when a reduction in dark areas was visible on FA.
CONCLUSIONS: No reperfusion of vessels or capillary network was detected in NP areas using 2 imaging techniques, UWF FA and SS-WF OCTA, in eyes with DR after 3 anti-VEGF injections. The detection rate of NP areas was higher with SS-WF OCTA than with UWF FA.
Copyright © 2019 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31383483     DOI: 10.1016/j.ophtha.2019.06.022

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  40 in total

1.  Quantification of Retinal Nonperfusion and Neovascularization With Ultrawidefield Fluorescein Angiography in Patients With Diabetes and Associated Characteristics of Advanced Disease.

Authors:  Gina Yu; Michael T Aaberg; Tapan P Patel; Rahul S Iyengar; Corey Powell; Annie Tran; Caitlin Miranda; Emma Young; Katarina Demetriou; Laxmi Devisetty; Yannis M Paulus
Journal:  JAMA Ophthalmol       Date:  2020-06-01       Impact factor: 7.389

2.  Retinal Nonperfusion in Proliferative Diabetic Retinopathy Before and After Panretinal Photocoagulation Assessed by Widefield OCT Angiography.

Authors:  Jonathan F Russell; Hasenin Al-Khersan; Yingying Shi; Nathan L Scott; John W Hinkle; Kenneth C Fan; Cancan Lyu; William J Feuer; Giovanni Gregori; Philip J Rosenfeld
Journal:  Am J Ophthalmol       Date:  2020-03-13       Impact factor: 5.258

3.  The prognostic value of peripheral retinal nonperfusion in diabetic retinopathy using ultra-widefield fluorescein angiography.

Authors:  Fares Antaki; Razek Georges Coussa; Mikel Mikhail; Cyril Archambault; David E Lederer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-07-16       Impact factor: 3.117

Review 4.  Statement of the German Ophthalmological Society, the German Retina Society, and the Professional Association of Ophthalmologists in Germany on treatment of diabetic macular edema : Dated August 2019.

Authors: 
Journal:  Ophthalmologe       Date:  2021-01       Impact factor: 1.059

5.  Correlation of Quantitative Measurements with Diabetic Disease Severity Using Multiple En Face OCT Angiography Image Averaging.

Authors:  Jesse J Jung; Daryle Jason G Yu; Anne Zeng; Michael H Chen; Yue Shi; Marco Nassisi; Kenneth M Marion; Srinivas R Sadda; Quan V Hoang
Journal:  Ophthalmol Retina       Date:  2020-05-07

Review 6.  Retinal non-perfusion in diabetic retinopathy.

Authors:  Charles C Wykoff; Hannah J Yu; Robert L Avery; Justis P Ehlers; Ramin Tadayoni; SriniVas R Sadda
Journal:  Eye (Lond)       Date:  2022-01-11       Impact factor: 3.775

Review 7.  Profile of non-responder and late responder patients treated for diabetic macular edema: systemic and ocular factors.

Authors:  Mariacristina Parravano; Eliana Costanzo; Giuseppe Querques
Journal:  Acta Diabetol       Date:  2020-02-29       Impact factor: 4.280

8.  Interaction Between the Distribution of Diabetic Retinopathy Lesions and the Association of Optical Coherence Tomography Angiography Scans With Diabetic Retinopathy Severity.

Authors:  Mohamed Ashraf; Konstantina Sampani; Abdulrahman Rageh; Paolo S Silva; Lloyd Paul Aiello; Jennifer K Sun
Journal:  JAMA Ophthalmol       Date:  2020-12-01       Impact factor: 7.389

9.  Long-term follow-up of diabetic macular edema treated with dexamethasone implant: a real-life study.

Authors:  Thibaud Mathis; Théo Lereuil; Amro Abukashabah; Nicolas Voirin; Aditya Sudhalkar; Alper Bilgic; Philippe Denis; Corinne Dot; Laurent Kodjikian
Journal:  Acta Diabetol       Date:  2020-07-12       Impact factor: 4.280

10.  Optical Coherence Tomography Angiography of Macular Perfusion Changes after Anti-VEGF Therapy for Diabetic Macular Edema: A Systematic Review.

Authors:  Ayman G Elnahry; Gehad A Elnahry
Journal:  J Diabetes Res       Date:  2021-05-22       Impact factor: 4.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.